Compound of formula (I): wherein: -A represents a 6- to 10-membered aryl group; a 5- to 12-membered heteroaryl group or a 4- to 12-membered heterocyclic group, A being optionally substituted with one or more substituents chosen among halogen atoms, hydroxyl, (C 1 -C 6 )alkyl, cyano, oxo, carbonyl; tert-butyloxycarbonyl, 1,3-dioxolanyl, 1,4-dioxolanyl, (C 1 -C 6 )alkoxy, -COOR 1 ,-CONR 1 R 2 and NR 1 R 2 , with said (C 1 -C 6 )alkyl being itself optionally substituted with a hydroxyl, NR 1 R 2 , (C 1 -C 6 )alkoxy, or -S(C 1 -C 6 )alkyl group, and said 4- to 12-membered heterocyclic group optionally comprising two fused cycles wherein the two cycles share at least two atoms; -L represents a linker chosen among linear or branched (C 1 -C 6 )alkylene group, said alkylene group being optionally substituted with at least one halogen, hydroxyl, (C 1 -C 6 )alkoxy, -COOR 1 or NR 1 R 2 groups; -B represents a 6- to 10-membered aryl or a 5- to 12-membered heteroaryl group with B being optionally substituted with one or more substituents chosen among halogen atoms, trifluoromethyl, trifluoromethoxy, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy,-CONR 1 R 2 , NR 1 R 2 , hydroxy(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy and (C 1 -C 6 )alkyl NR 1 R 2 groups; with two adjacent carbon atoms of said 6- to 10-membered aryl group being optionally substituted by two oxygen atoms linked together by a (C 1 -C 6 )alkylene group, - R 1 and R 2 represent, independently of each other, a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group, a hydroxy(C 1 -C 6 )alkyl group or a hydroxy(C 1 -C 6 )alkoxy group, or one of its pharmaceutically acceptable salts. -A represents a 6- to 10-membered aryl group; a 5- to 12-membered heteroaryl group or a 4- to 12-membered heterocyclic group, A being optionally substituted with one or more substituents chosen among halogen atoms, hydroxyl, (C 1 -C 6 )alkyl, cyano, oxo, carbonyl; tert-butyloxycarbonyl, 1,3-dioxolanyl, 1,4-dioxolanyl, (C 1 -C 6 )alkoxy, -COOR 1 ,-CONR 1 R 2 and NR 1 R 2 , with said (C 1 -C 6 )alkyl being itself optionally substituted with a hydroxyl, NR 1 R 2 , (C 1 -C 6 )alkoxy, or -S(C 1 -C 6 )alkyl group, and said 4- to 12-membered heterocyclic group optionally comprising two fused cycles wherein the two cycles share at least two atoms; -L represents a linker chosen among linear or branched (C 1 -C 6 )alkylene group, said alkylene group being optionally substituted with at least one halogen, hydroxyl, (C 1 -C 6 )alkoxy, -COOR 1 or NR 1 R 2 groups; -B represents a 6- to 10-membered aryl or a 5- to 12-membered heteroaryl group with B being optionally substituted with one or more substituents chosen among halogen atoms, trifluoromethyl, trifluoromethoxy, hydroxyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy,-CONR 1 R 2 , NR 1 R 2 , hydroxy(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy(C 1 -C 6 )alkoxy and (C 1 -C 6 )alkyl NR 1 R 2 groups; with two adjacent carbon atoms of said 6- to 10-membered aryl group being optionally substituted by two oxygen atoms linked together by a (C 1 -C 6 )alkylene group, - R 1 and R 2 represent, independently of each other, a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group, a hydroxy(C 1 -C 6 )alkyl group or a hydroxy(C 1 -C 6 )alkoxy group, or one of its pharmaceutically acceptable salts. <EOS>